Serbia to start producing Chinese Sinopharm vaccine

vaccine
Credit: Unsplash/CC0 Public Domain

Serbia will become the first European country to produce the Chinese Sinopharm coronavirus vaccine, the Balkan country's President Aleksandar Vucic said Thursday.

Vucic announced that a deal concerning the construction of a "vaccine factory" will be signed in the next two weeks, and it will be built with support of China and United Arab Emirates.

"We will start producing the vaccine as soon as October 15", Vucic told public broadcaster RTS after a meeting with the UAE's de facto ruler Sheikh Mohammed bin Zayed al Nahyan in Abu Dhabi.

Although an EU-candidate country, Serbia has kept close diplomatic and economic ties with Moscow and Beijing, and has used the delicate balance to become continental Europe's fastest vaccinator.

The small Balkan country has secured massive shipments of Sinopharm and Russia's Sputnik V jab, leading the Balkan country to inoculate some 1.5 million of its 7 million population.

While the European Union kicked off its vaccination programme across its 27 member states late December, outside its borders in the Western Balkans have been left to fend for their own.

Vucic, in comments run by the RTS public broadcaster, added that once the factory is set up, Serbia will provide the vaccine to countries throughout the region.

"What I learned tonight is that we will have to give the vaccine around the region, even at production cost", Vucic said.

In February, Serbia was given preliminary approval to start manufacturing the Sputnik V as well, and has said production will begin in mid-May.


Explore further

Serbia starts vaccination with Chinese-made Sinopharm

© 2021 AFP

Citation: Serbia to start producing Chinese Sinopharm vaccine (2021, March 11) retrieved 18 October 2021 from https://medicalxpress.com/news/2021-03-serbia-chinese-sinopharm-vaccine.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors